NASDAQ:KYTX Kyverna Therapeutics Q2 2026 Earnings Report $7.78 +0.28 (+3.66%) Closing price 03:59 PM EasternExtended Trading$7.79 +0.00 (+0.06%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kyverna Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.67Beat/MissN/AOne Year Ago EPSN/AKyverna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKyverna Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Kyverna Therapeutics Earnings HeadlinesKyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program AdvancementJuly 29, 2026 | seekingalpha.comKyverna secures long-term miv-cel manufacturing partnershipJuly 27, 2026 | tipranks.com1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-known name may be positioned to benefit while the Magnificent 7 stumbles. Smaller, overlooked stocks are showing growing potential to challenge AI's biggest players. One specific ticker stands out heading into that date.August 4 at 1:00 AM | Chaikin Analytics (Ad)Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celJuly 27, 2026 | globenewswire.comKyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor FocusJuly 25, 2026 | theglobeandmail.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 25, 2026 | americanbankingnews.comSee More Kyverna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email. Email Address About Kyverna TherapeuticsKyverna Therapeutics (NASDAQ:KYTX) is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression. The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts. Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.View Kyverna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise QuarterThe AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic Win Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
